Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of tislelizumab plus cetuximab and irinotecan in patients with previously treated RAS wild-type advanced colorectal cancer: A phase II, single-arm study.
Authors
Xiaojing Xu
Department of Oncology, Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China;
Xiaojing Xu , Yiyi Yu , Yan Wang , Yuehong Cui , Wei Li , Li Liang , Qian Li , Shan Yu , Yi Feng , Qing Liu , Pengfei Zhang , Minzhi Lv , Tianshu Liu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05143099
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 125)
DOI
10.1200/JCO.2023.41.4_suppl.125
Abstract #
125
Poster Bd #
G3
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Efficacy and safety of tislelizumab plus cetuximab and irinotecan in patients with previously treated RAS wild-type advanced colorectal cancer: Preliminary findings of a phase II, single-arm study.
First Author: Xiaojing Xu
Poster
2023 ASCO Annual Meeting
A phase Ib/II study to evaluate surufatinib combined with camrelizumab and chemotherapy in the second-line treatment of advanced colorectal cancer: Phase Ib results.
First Author: Sheng Li
Poster
2022 ASCO Annual Meeting
Phase 2 study of anti-EGFR rechallenge therapy with panitumumab with or without trametinib in advanced colorectal cancer.
First Author: Christine Megerdichian Parseghian
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase 1b/2 study of VS-6766 in combination cetuximab in patients (pts) with advanced KRAS mt colorectal cancer (CRC).
First Author: Ardaman Shergill